Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance-Reference-Cited by-同舟云学术

Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance

Published:2014-06-19 Issue:10 Volume:69 Page:2741-2745
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:Journal of Antimicrobial Chemotherapy

Author:

Muniz C. P.,Soares M. A.,Santos A. F.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Reference24 articles.

1. HIV Genetic Diversity and Drug Resistance

2. Global trends in molecular epidemiology of HIV-1 during 2000–2007

3. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses

4. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial;Journal of the International AIDS Society;2021-11

2. Identification of Novel Resistance-Related Polymorphisms in HIV-1 Subtype C RT Connection and RNase H Domains from Patients Under Virological Failure in Brazil;AIDS Research and Human Retroviruses;2017-05

3. Drug resistance-related mutations T369V/I in the connection subdomain of HIV-1 reverse transcriptase severely impair viral fitness;Virus Research;2017-04

4. Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa;Antimicrobial Agents and Chemotherapy;2017-02

5. Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing;Future Virology;2016-11